Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.

Brian Green

Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.

School of Biological Sciences

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	3651-3662
Number of pages	12
Journal	Current Pharmaceutical Design
Volume	10(29)
Issue number	29
Publication status	Published - 2004

ASJC Scopus subject areas

Molecular Medicine
Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{abac573c6067472284e499fbc996795f,

title = "Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.",

author = "Brian Green",

year = "2004",

language = "English",

volume = "10(29)",

pages = "3651--3662",

journal = "Current Pharmaceutical Design",

publisher = "Bentham Science Publishers",

number = "29",

}

TY - JOUR

T1 - Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.

AU - Green, Brian

PY - 2004

Y1 - 2004

UR - http://www.scopus.com/inward/record.url?scp=6344241190&partnerID=8YFLogxK

M3 - Article

C2 - 15579061

VL - 10(29)

SP - 3651

EP - 3662

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

IS - 29

ER -

Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.

ASJC Scopus subject areas

Other files and links

Cite this